Stephens Investment Management Group LLC Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN)
Stephens Investment Management Group LLC lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 151,503 shares of the life sciences company’s stock after selling 16,600 shares during the quarter. Illumina accounts for 1.1% of Stephens Investment Management Group LLC’s portfolio, making the stock its 26th biggest holding. Stephens Investment Management Group LLC owned about 0.10% of Illumina worth $55,776,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Strategy Asset Managers LLC purchased a new position in Illumina during the 1st quarter valued at $26,000. C J Advisory Inc purchased a new position in Illumina during the 1st quarter valued at $29,000. Valeo Financial Advisors LLC boosted its holdings in Illumina by 130.0% during the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock valued at $36,000 after acquiring an additional 65 shares during the period. Mizuho Securities Co. Ltd. purchased a new position in Illumina during the 1st quarter valued at $37,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in Illumina during the 2nd quarter valued at $37,000. Institutional investors own 90.95% of the company’s stock.
Several brokerages have weighed in on ILMN. Cowen lowered their target price on Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, July 12th. Piper Jaffray Companies lowered their target price on Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a report on Tuesday, July 30th. Bank of America cut Illumina from a “buy” rating to an “underperform” rating and set a $310.00 target price for the company. in a report on Friday, July 12th. UBS Group upped their target price on Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Finally, ValuEngine upgraded Illumina from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $330.92.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.43 EPS. Sell-side analysts predict that Illumina, Inc. will post 6.04 earnings per share for the current year.
In other news, SVP Robert P. Ragusa sold 2,230 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total value of $653,590.70. Following the completion of the transaction, the senior vice president now directly owns 10,685 shares of the company’s stock, valued at approximately $3,131,666.65. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $304.44, for a total value of $1,004,652.00. Following the completion of the transaction, the director now directly owns 282,516 shares of the company’s stock, valued at $86,009,171.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,458 shares of company stock valued at $16,527,618. Corporate insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Portfolio Manager
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.